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Rates of virological failure in patients treated in a 
home-based versus a facility-based HIV-care model in Jinja, 
southeast Uganda: a cluster-randomised equivalence trial 
Shabbar Jaﬀ ar, Barbara Amuron, Susan Foster, Josephine Birungi, Jonathan Levin, Geoﬀ rey Namara, Christine Nabiryo, Nicaise Ndembi, 
Rosette Kyomuhangi, Alex Opio, Rebecca Bunnell, Jordan W Tappero, Jonathan Mermin, Alex Coutinho, Heiner Grosskurth, on behalf of the 
Jinja trial team* 
Summary
Background Identiﬁ cation of new ways to increase access to antiretroviral therapy in Africa is an urgent priority. We 
assessed whether home-based HIV care was as eﬀ ective as was facility-based care.
Methods We undertook a cluster-randomised equivalence trial in Jinja, Uganda. 44 geographical areas in nine strata, 
deﬁ ned according to ratio of urban and rural participants and distance from the clinic, were randomised to 
home-based or facility-based care by drawing sealed cards from a box. The trial was integrated into normal service 
delivery. All patients with WHO stage IV or late stage III disease or CD4-cell counts fewer than 200 cells per μL who 
started antiretroviral therapy between Feb 15, 2005, and Dec 19, 2006, were eligible, apart from those living on 
islands. Follow-up continued until Jan 31, 2009. The primary endpoint was virological failure, deﬁ ned as RNA more 
than 500 copies per mL after 6 months of treatment. The margin of equivalence was 9% (equivalence limits 0·69–1·45). 
Analyses were by intention to treat and adjusted for baseline CD4-cell count and study stratum. This trial is registered 
at http://isrctn.org, number ISRCTN 17184129.
Findings 859 patients (22 clusters) were randomly assigned to home and 594 (22 clusters) to facility care. During the 
ﬁ rst year, 93 (11%) receiving home care and 66 (11%) receiving facility care died, 29 (3%) receiving home and 36 (6%) 
receiving facility care withdrew, and 8 (1%) receiving home and 9 (2%) receiving facility care were lost to follow-up. 
117 of 729 (16%) in home care had virological failure versus 80 of 483 (17%) in facility care: rates per 100 person-years 
were 8·19 (95% CI 6·84–9·82) for home and 8·67 (6·96–10·79) for facility care (rate ratio [RR] 1·04, 0·78–1·40; 
equivalence shown). Two patients from each group were immediately lost to follow-up. Mortality rates were similar 
between groups (0·95 [0·71–1·28]). 97 of 857 (11%) patients in home and 75 of 592 (13%) in facility care were admitted 
at least once (0·91, 0·64–1·28). 
Interpretation This home-based HIV-care strategy is as eﬀ ective as is a clinic-based strategy, and therefore could enable 
improved and equitable access to HIV treatment, especially in areas with poor infrastructure and access to clinic care. 
Funding US Centers for Disease Control and Prevention and UK Medical Research Council.
Introduction
Antiretroviral drug therapy has been scaled up rapidly in 
Africa, and is now given to more than 2 million people.1 
A global commitment has been made to provide universal 
coverage,2 but another 5 million people, mostly living in 
rural and semiurban areas, are estimated to need such 
treatment. Achievement of high coverage in these 
populations will be a challenge. Two major barriers to 
increasing coverage exist—a severe shortage of clinically 
qualiﬁ ed staﬀ , which has reached crisis point in most of 
Africa,3 and diﬃ  culty for patients in accessing clinics 
because of high costs and poor availability of transport 
and low-cash incomes.4,5 
WHO proposes decentralised antiretroviral therapy 
delivery,6,7 and so far services for such therapy have been 
pro vided through nurse-led centres with simpliﬁ ed proto-
cols in several settings, including in Malawi,8,9 Zambia,10 
Mozambique,11 Botswana,12 and South Africa.13 Good patient 
outcomes have been reported8,10 from short-term assess-
ments done in some sites, but interpretation of this 
evidence is diﬃ  cult because of poor retention rates.14 
Further more, nursing staﬀ  as well as doctors are in very 
short supply3,15 and care needs to be delegated to non-clinical 
workers, although evidence for use of non-clinical workers 
in HIV care is scarce. In Tororo, Uganda, a home-based 
programme16,17 with lay workers has achieved good out-
comes, but it consisted of home visits made every week 
with good access to clinical staﬀ  when needed—a model 
that would be diﬃ  cult to scale up. No direct comparisons of 
hospital-based HIV care versus any form of decentralised 
HIV care have been done in Africa. We assessed home-based 
HIV care, with lay workers delivering antiretroviral therapy 
and monitoring patients, versus facility-based HIV care.
Methods
Study setting and patients
We undertook a trial based at the AIDS Support 
Organisation (TASO) clinic in Jinja district, southeast 
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Uganda.18 TASO is a large non-governmental organisation 
with 11 centres in the country, oﬀ ering counselling and 
social and clinical services to people with HIV. The Jinja 
district and surrounding area is poor, with inhabitants on 
low-cash incomes.18 TASO clinic serves a predominantly 
rural and semiurban population from a radius of about 
100 km. Most TASO clients are subsistence farmers, and 
very few work in the formal sector earning wages. 
In accordance with guidelines from the Ugandan 
Ministry of Health, people with HIV were eligible to start 
antiretroviral therapy if they were assessed to be at WHO 
stage IV or late stage III disease, or if they had a CD4-cell 
count of fewer than 200 cells per μL. Eligible patients were 
prepared for therapy by TASO staﬀ  during three visits to 
clinic, which were usually spread over 4 weeks. Information 
and counselling were provided both in groups and in 
one-to-one sessions. Participants were given drugs for 
28 days of treatment and issued with a pill box. A buﬀ er 
supply for 2 days was provided. Patients were also strongly 
encouraged to identify a so-called medicine companion to 
provide support and reminders. Medicine companions 
were given information by TASO about the basic principles 
of antiretroviral therapy and adherence. 
All TASO patients older than 18 years who were 
starting on antiretroviral therapy for the ﬁ rst time were 
invited to join the trial, apart from those living on 
islands, which were about 100 km away and where 
provision of home-based care was not possible. All 
patients provided written informed consent. The trial 
protocol was approved by the Ugandan National Council 
of Science and Technology and the Institutional Review 
Boards of the Uganda Virus Research Institute, Centers 
for Disease Control and Prevention, and London School 
of Hygiene and Tropical Medicine. Patients were 
informed about their rights to refuse to join the trial or 
withdraw subsequently. Those who did were oﬀ ered 
facility-based HIV care (including antiretroviral therapy) 
from TASO Jinja. 
Study design
Recruitment began Feb 15, 2005, and ended Dec 19, 2006, 
and follow-up continued until Jan 31, 2009. Numbers of 
patients eligible for antiretroviral therapy were not known 
in advance—participants were identiﬁ ed after they were 
tested for CD4-cell counts and clinically assessed. The 
catchment area was divided into nine strata according to 
ratio of urban and rural participants and approximate 
distance from a central point to the TASO Jinja clinic. In 
every stratum, an even number of clusters (geographical 
areas) were deﬁ ned for randomisation along subdistrict 
boundaries, or, in the case of a few large subdistricts, by 
known barriers within the subdistrict. Clusters in every 
stratum had a similar estimated number of people with 
HIV who were registered at TASO Jinja. Distribution of 
strata and clusters was as follows: (1) four clusters in 
urban areas or near the TASO Jinja facility; (2) eight in 
periurban intermediate distance; (3) eight in rural and 
far; (4) four in Kamuli district; (5) four in Mukono district 
near; (6) six in Mukono district far; (7) six in Mayuge 
district; (8) two in Iganga district near; and (9) two in 
Iganga district far. Strata and clusters were devised by 
two people with knowledge of the area (one TASO staﬀ  
member and one researcher) and cross-checked 
independently by two other people on two separate 
occasions. 
For all patients, antiretroviral therapy was started at the 
TASO Jinja clinic, and thereafter patients received care 
according to the treatment to which their residential area 
had been assigned. After giving consent, patients were 
enrolled into the study by research staﬀ , and their 
addresses were conﬁ rmed from TASO records. At every 
clinic visit, research staﬀ  interviewed participants in 
2566 HIV patients assessed for
antiretroviral therapy
880 eligible
859 enrolled
22 clusters analysed
729 patients analysed
662 alive and being 
followed up at end 
of study
22 clusters analysed
483 patients analysed
441 alive and being 
followed up at end 
of study
594 enrolled
21 refused
19 feared disclosure of HIV
status
1 about to leave the area
1 had child living elsewhere
receiving facility care and
wanted to be in the same
group
59 withdrew
25 moved out of catchment 
area
6 changed service provider
5 transferred to other TASO
centres
14 could not aﬀord transport
7 feared disclosure of HIV
status
1 withdrew because of
treatment side-eﬀects
1 claimed to have been 
healed
14 lost to follow-up
80 deaths
60 withdrew 
28 moved out of catchment
area
3 changed service provider 
11 transferred to other TASO
centres
6 could not aﬀord transport 
12 feared disclosure of HIV
status
20 lost to follow-up 
117 deaths
3 refused
3 feared disclosure of HIV
status
1698 HIV patients assessed for
antiretroviral therapy
597 eligible
22 clusters allocated to 
facility-based care
22 clusters allocated to 
home-based care
44 geographical areas (clusters) stratiﬁed in nine strata according 
to estimated numbers of people with HIV and distance from 
clinic and randomised
Figure 1: Trial proﬁ le
TASO=The AIDS Support Organisation.
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privacy in a separate building soon after their arrival and 
before they saw TASO staﬀ .19
Randomisation
Clusters in each strata were allocated to either home-
based or facility-based care by drawing cards from a 
concealed box. The cards were sealed in advance and 
labelled with the stratum number by the trial coordinator 
and TASO senior medical oﬃ  cer who organised the 
allocation event and placed the cards into the box for each 
stratum. Cards were drawn by two patient representatives, 
a TASO medical oﬃ  cer, TASO counsellor, and TASO ﬁ eld 
oﬃ  cer, each taking turns. This process was done in the 
presence of senior TASO staﬀ , researchers, and local 
public health representatives.
Models of care
The trial was done in conditions similar to those of actual 
health services, with TASO staﬀ  responsible for service 
delivery.19 Numbers of counsellors, nurses, and laboratory 
and pharmacy staﬀ  in Jinja were similar to those at other 
TASO centres. The clinic had ﬁ ve medical oﬃ  cers but the 
number present usually varied between two and four, 
with some support from local part-time physicians 
during the trial. Most medical oﬃ  cers were newly 
qualiﬁ ed. Clinical staﬀ  were trained on antiretroviral 
therapy and supported by a senior medical oﬃ  cer.
For the home-based group, trained ﬁ eld oﬃ  cers 
travelling on motorcycles visited patients at home every 
month to deliver drugs, monitor participants with a 
checklist that included signs and symptoms of drug 
toxicity or disease progression, and provide adherence 
support. Most ﬁ eld oﬃ  cers had degree qualiﬁ cations or 
college diplomas and underwent 4 weeks of intensive 
training at the start of the study and yearly refresher 
courses thereafter about the principles of antiretroviral 
therapy and adherence support. They were supported at 
the TASO clinic by counsellors and medical oﬃ  cers. 
Field oﬃ  cers referred patients to a physician or 
counsellor at the TASO clinic when they judged referral 
to be necessary. They had mobile phones and could 
contact physicians when unsure about referral. At the end 
of every day, a medical oﬃ  cer reviewed the notes made by 
ﬁ eld oﬃ  cers and, when needed, asked oﬃ  cers to return to 
the patient’s home to refer them. Patients who were not at 
home for their monthly appointment were visited 
again—usually the next day. If they were absent again, 
ﬁ eldworkers left a message for them to come to the clinic. 
All patients were invited to the clinic for routine reviews 
by a medical oﬃ  cer and a counsellor at 2 and 6 months 
after starting therapy and every 6 months thereafter. 
Drugs were not dispensed during clinic visits for those 
allocated to home-based case. Before antiretroviral therapy 
started, TASO oﬀ ered free voluntary counselling and 
testing in the home to household members of participants. 
This oﬀ er was repeated during home visits for drug 
delivery for those who were absent previously. 
In the facility-based group, patients obtained drugs 
every month from the clinic and had routine reviews 
with a medical oﬃ  cer and counsellor that were 
scheduled at 2 and 3 months after start of treatment 
and every 3 months thereafter. Apart from scheduled 
reviews, patients were assessed during clinic visits by a 
nurse and referred to a doctor when necessary. When 
Home-based care (n=859) Facility-based care (n=594)
Female sex 625 (73%) 406 (68%)
Age (years) 37 (32–44) 38 (33–44)
Education
No education 151 (18%) 83 (14%)
Primary 484 (56%) 332 (56%)
Secondary or tertiary 224 (26%) 179 (30%)
Marital status
Married or cohabiting 300 (35%) 216 (36%)
Widowed 351 (41%) 232 (39%)
Divorced or separated 194 (23%) 137 (23%)
Single 14 (2%) 9 (2%)
Median time taken to reach clinic (h) 1·0 (0·5–2·0) 1·25 (1·0–2·0)
Main form of transport to clinic
Walking 36 (4%) 31 (5%)
Minibus or car taxi 716 (83%) 479 (81%)
Motorbike or bicycle taxi 66 (8%) 51 (8%)
Other 41 (5%) 33 (5%)
WHO stage
I 14 (2%) 6 (1%)
II 384 (45%) 258 (43%)
III 390 (45%) 283 (48%)
IV 71 (8%) 47 (8%)
CD4-cell count (cells per μL)
<50 272 (32%) 172 (29%)
50–99 159 (19%) 73 (12%)
100–149 170 (20%) 136 (23%)
150–199 171 (20%) 168 (28%)
≥200 87 (10%) 45 (8%)
Median (IQR) 99 (34–162) 122 (30 –167)
Plasma viral load copies per mL
<1000 12 (1%) 9 (2%)
1000–9999 21 (2%) 19 (3%)
10 000–99 999 252 (29%) 202 (34%)
100 000–999 999 514 (60%) 318 (54%)
≥1 000 000 60 (7%) 46 (8%)
Median (IQR) 173 000 (69 000–380 000) 151 700 (58 600–359 000)
Antiretroviral therapy prescription at enrolment
Stavudine, lamivudine, nevirapine 401 (47%) 269 (45%)
Stavudine, lamivudine, efavirenz 75 (9%) 61 (10%)
Zidovudine, lamivudine, nevirapine 253 (29%) 188 (32%)
Zidovudine, lamivudine, efavirenz 129 (15%) 75 (13%)
Tenofovir, lamivudine and nevirapine 0 1 (<1%)
Tenofovir, lamivudine and efavirenz 1 (<1%) 0
Data are n (%) or median (IQR).
Table 1: Baseline social and demographic characteristics of home-based and facility-based care groups 
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an appoint ment was missed, patients were followed up 
at home by a ﬁ eld oﬃ  cer (if patients had given 
permission for home visits), usually after 2–3 days, and 
reminded to attend clinic. Participants were also given 
vouchers for their household for free voluntary 
counselling and testing at TASO Jinja. Patients in both 
groups were asked to come to the clinic any time that 
they felt unwell. They were also given a telephone 
number to call for advice. In exceptional cases, and 
when TASO resources allowed, home care was provided 
by a team, including a physician, to patients who were 
bedridden. No ﬁ nancial or other incentives were 
provided to patients or staﬀ  and TASO clinical 
management procedures were identical for trial and 
non-trial participants.
Procedures
Independent research staﬀ  assessed adherence.19 Patients 
in both groups were interviewed during routine clinical 
and counselling visits at 2 months and 6 months after 
starting therapy and then every 6 months. Questionnaires 
were translated into the local language, Luganda, and 
then back into English by an independent person, and 
cross-checked by another researcher who was not 
involved with the trial.
Clinical data were transcribed from patient notes. A 
change to a second-line regimen was decided by a TASO 
case conference, consisting of physicians and counsellors, 
and was made when a patient had one of the following 
criteria: (1) new or recurrent WHO clinical stage IV or 
advanced stage III disease; (2) clinical deterioration (eg, 
weight loss) and two or more consecutive CD4-cell counts 
less than baseline, or a fall to 50% less than peak CD4-cell 
count attained after the start of antiretroviral therapy; or 
(3) CD4-cell counts persistently fewer than 100 cells 
per μL. Survival status was established through home 
Home-based care (n=859) Facility-based care (n=594) Adjusted rate ratio 
(95% CI)*
Number of 
events (%)
Rate per 100 person-
years (95% CI)
Number of 
events (%)
Rate per 100 person-
years (95% CI)
Plasma RNA VL >500 copies per mL†‡ 117/729 (16%) 8·19 (6·84–9·82) 80/483 (17%) 8·67 (6·96–10·79) 1·04 (0·78–1·40)
Either plasma RNA VL >500 copies per mL‡ if 
undetectable at 6 months, or an increase of 
1000 copies between two consecutive tests if RNA 
detectable at 6 months†
106/729 (15%) 7·33 (6·06–8·86) 74/483 (15%) 7·88 (6·28–9·90) 0·99 (0·73–1·34)
All-cause mortality§ 117/857 (14%) 5·40 (4·51–6·47) 80/592 (14%) 5·51 (4·42–6·86) 0·95 (0·71–1·28)
Mortality or plasma RNA VL >500 copies per mL‡§ 226/857 (26%) 11·29 (9·91–12·86) 152/592 (26%) 11·45 (9·76–13·42) 1·03 (0·83–1·27)
Admitted on one or more occasions§|| 97/857 (11%) 5·16 (4·23–6·29) 75/ 592 (13%) 6·11 (4·87–7·66) 0·91 (0·64–1·28)
All admissions 116 5·86 (4·89–7·03) 84 6·37 (5·14–7·89) 0·99 (0·69–1·42)
Death, ﬁ rst admission, or change to second-line 
therapy§
170/857 (20%) 9·04 (7·78–10·51) 138/592 (23%) 11·24 (9·52–13·29) 0·81 (0·64–1·02)
 VL=viral load. *Adjusted for study stratum and CD4-cell count categorised as 0–49, 50–99, 100–149, and 150 or more cells per μL. †Patients not followed up for 1 year were 
excluded. Home-based group, 93 (11%) died, 29 (3%) withdrew, and eight (1%) lost to follow-up; facility-based group 66 (11%) died, 36 (6%) withdrew, and nine (2%) were 
lost to follow-up. ‡After 6-monthly visit. §74 (9%) deaths in home-based and 57 (10%) in facility-based care took place at home. Two home and two facility patients were 
immediately lost to follow-up. || Variable analysed is the time to ﬁ rst admission.
Table 2: Rates of virological failure, mortality, and admission by group
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Figure 2: Kaplan-Meier curve of HIV-RNA virological suppression (A) and survival (B)
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follow-ups or hospital records, dependent on where 
deaths took place. We established the status of participants 
who withdrew from TASO records. 
CD4-cell counts were monitored by TASO staﬀ  every 
6 months for all patients as part of their clinical care.
CD4-positive cells were measured with TriTEST reagents 
(Becton-Dickenson, Franklin Lakes, NJ, USA), according 
to an inhouse dual-platform protocol and MultiSET and 
Attractors software (version 2.2) with a FACScan ﬂ ow 
cytometer (Becton-Dickinson, Franklin Lakes, NJ, USA). 
Additional blood was taken to measure plasma viral 
load, but this testing was for research reasons and done 
in batches later. Plasma was separated within 2 h and 
stored immediately at –80ºC. HIV-1 RNA was tested 
with the VERSANT RNA 3.0 (Bayer, Bayer HealthCare, 
NY, USA) assay (with a lower limit of detection of 
50 copies per mL) for baseline samples, and the 
Amplicor MONITOR 1.5 (Roche, Roche Molecular 
Systems, NJ, USA) for other samples (400 per copies per 
mL). After we established close correlation between 
results of the two assays, the Amplicor assay was used to 
keep costs to a minimum. 
Our economic analysis took a societal perspective and 
included recurrent and capital costs incurred by the 
provider, transport and other related costs, and income 
lost by patients while accessing care. We reported all 
costs in 2008 US$; the mean exchange rate from 2005 to 
2008 was 1732 Ugandan shillings to $1. Cost data and all 
data for care provided by TASO were obtained from 
TASO accounts. We used three steps to allocate costs. 
First, we established the proportion of all TASO clients 
who were receiving antiretroviral therapy. Second, we 
calculated the percentage of TASO clients on therapy 
who entered the trial. Both percentages changed over 
time, rising initially as numbers of patients who were put 
on therapy increased, and then falling when recruitment 
stopped. To capture this dynamic situation, we gathered 
and aggregated monthly cost data every 6 months, and 
converted data to US$ with the prevailing exchange rate, 
with adjustment for inﬂ ation. 
Third, we allocated costs to facility and home groups. 
When possible, we used actual service data—eg, 
information about numbers of doctor visits was used to 
allocate staﬀ  time. We assigned antiretroviral therapy 
costs proportionally by patient numbers in both groups 
for that period. Drug prices included purchase cost, 
insurance, and freight to Uganda and were adjusted to 
account for substantial price reductions that occurred 
early in the project. We established costs incurred by 
patients through a questionnaire. 
Health-services costs consisted of: staﬀ  costs (doctors, 
ﬁ eld oﬃ  cers, cousellors, and other staﬀ ), transport 
(motorcycle and vehicle costs of fuel and maintenance, 
and other transport costs); all drugs; laboratory and 
clinical expenses (radiograph, ultrasound, and laboratory 
and CD4 tests); sensitisation (AIDS education via radio, 
other media, and drama); training, teambuilding, and 
workshops; utilities (electricity, telephone, postage, and 
security), supervision and overheads (stationery, repairs, 
overheads, and supervision costs), and capital costs 
(buildings, furniture, vehicles, equipment, and inventory). 
Buildings depreciated over 50 years and other elements 
5 years (eg, The AIDS Support Organisation practice). 
Patient costs consisted of: cost of transport (including 
transport of medicine companion), childcare, and 
lunches, if applicable, median weighted by proportion 
($2·88 for women and $3·46 for men); and lost work 
time, estimated 1 day for clinic visits and 0·5 days for 
home visits, valued at Uganda mean per head gross 
domestic product from 2005–08 (World Bank data) for 
300 working days per year.
The primary endpoint was rate of virological failure, 
deﬁ ned as time (starting from 6 months) to a plasma 
Home-based care 
(n=859)
Facility-based 
care (n=594)
Malaria 24 (25%) 28 (37%)
Bronchopneumonia 17 (18%) 14 (19%)
Lobar pneumonia 1 (1%) 1 (1%)
Anaemia 12 (12%) 3 (4%)
Pulmonary tuberculosis 7 (7%) 5 (7%)
Extrapulmonary tuberculosis 2 (2%) 0
Kaposi’s sarcoma 3 (3%) 2 (3%)
Bacterial meningitis 4 (4%) 1 (1%)
Cryptocococcal meningitis 2 (2%) 2 (3%)
Gastroenteritis 2 (2%) 3 (4%)
Dehydration 1 (1%) 1 (1%)
Diarrhoea 1 (1%) 0
Abscess 2 (2%) 0
Oesophageal candidosis 1 (1%) 1 (1%)
Stevens–Johnson syndrome 2 (2%) 0
Pleural eﬀ usion 1 (1%) 1 (1%)
Psychosis 2 (2%) 0
Herpes simplex labial 1 (1%) 0
Herpes zoster 0 1 (1%)
Arthritis 0 1 (1%)
Cervical cancer 0 1 (1%)
Congestive cardiac failure 1 (1%) 0
Enteric fever 0 1 (1%)
Fibroids 1 (1%) 0
HIV wasting syndrome 1 (1%) 0
Hypertension 0 1 (1%)
Intrauterine fetal death 0 1 (1%)
Liver cirrhosis 1 (1%) 0
Osteomyelitis 0 1 (1%)
Tetanus 1 (1%) 0
Toxoplasmosis 1 (1) 0
Urinary tract infection 0 1 (1%)
Other diagnoses 6 (6%) 5 (7%)
Data are n (%).
Table 3: Diagnoses at ﬁ rst admission after start of antiretroviral therapy
For the TriTEST reagents 
protocol see http://www.
bdbiosciences.com/external_
ﬁ les/is/doc/tds/Package_Inserts_
IVD/live/web_enabled/23-3525-02_
Tri4_8_3_IVD_Eng.pdf
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RNA viral load of more than 500 copies per mL. The 
secondary outcome measures were time to either detect-
able plasma viral load of more than 500 copies per mL at 
any visit from 12 months onwards in patients with viral 
loads of fewer than 500 copies per mL at 6 months, or an 
increase of 1000 copies per mL between two consecutive 
tests in those not achieving a viral load of fewer than 
500 copies per mL at 6 months. Other secondary 
outcomes were all-cause mortality; virological failure as 
deﬁ ned in the primary outcome or death; time to ﬁ rst 
admission; death, admission, or change to second-line 
antiretroviral therapy; outpatient attendance; adherence 
during the previous 28 days (measured with a 
standardised questionnaire); and costs incurred by the 
health service and patients.
Statistical analysis
We designed the study as an equivalence trial. Virological 
failure time was taken as halfway between the last 
measure of RNA of 500 copies per mL or fewer and the 
ﬁ rst of more than 500 copies per mL. Testing was 
repeated in patients who had viral loads between 500 and 
1000 copies per mL to exclude the possibility of small 
transient increases. We assumed that in one group the 
rate of virological failure during follow-up would be 
about 20%,20–22 and that the other group could be regarded 
as equivalent if the rate of virological failure did not 
exceed 20% by more than 9%—ie, 29% or less. Thus, the 
upper limit of our equivalence interval was 29/20 or 
1·45, and by symmetry the lower limit was 20/29 or 
0·69. A sample size of 20 clusters per group with a total 
of 1200 participants gave more than 95% power to show 
equivalence, on the assumption of a between-cluster 
coeﬃ  cient of variation of 0·2.
Analysis was by intention to treat, in which all 
participants were regarded as randomly assigned to the 
group corresponding to the cluster in which they lived. 
Analyses were done for the individual by ﬁ tting 
generalised linear mixed models with a log-link and 
poisson distribution, with every patient contributing an 
outcome of 1 if they had virological failure and 0 if they 
did not. The model had ﬁ xed terms for study regions, 
baseline CD4-cell counts (categorised as a four-level 
factor with counts of 0–49, 50–99, 100–149, and 150 or 
more cells per μL), and study groups, with the log of 
exposure time included as an oﬀ set variable, and a 
random term for study cluster. The model was ﬁ tted with 
the assumption that the random cluster eﬀ ects followed 
a γ distribution. For the primary endpoint, exposure time 
was calculated from the 6-month visit to midway between 
the last date on which the patient did not have virological 
failure and the date of virological failure. For other 
endpoints, exposure time was calculated from enrolment. 
Those who withdrew or were lost to follow-up before 
12 months were excluded from the primary endpoint 
analysis, and for other endpoints they were censored on 
the last date seen. 
Role of the funding source
Sponsor staﬀ  had a role in the study design, data 
collection, data analysis, data interpretation, and writing 
of the report. The corresponding author had full access 
to the data and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Figure 1 shows the trial proﬁ le. The two groups were well 
balanced according to baseline characteristics apart from 
CD4-cell count, which was lower in the home-based than 
in the facility-based group (table 1). The median cluster 
size for home-based care was 36 people (range 6–84) and 
for facility-based care was 25 (2–65). Overall, 1403 patients 
(97%) were taking co-trimoxazole prophylaxis and 101 
(7%) were being treated for tuberculosis. 119 patients 
withdrew during the course of the trial. Their status at 
the end of the trial was: three (3%, one from the facility 
and two from the home group) had died, 98 (82%, 
48 facility and 50 home) were receiving antiretroviral 
therapy, one (<1%, facility) was alive and not receiving 
antiretroviral therapy, and 17 (15%, eight home and nine 
facility) were no longer in contact with TASO. The 
median follow-up of survivors on home-based care was 
28 months (IQR 18–35) and on facility-based care was 
27 months (13–34). 
Table 2 shows rates of virological failure, death, and 
hospital admission by group. Figure 2 shows HIV-RNA 
virological suppression and survival over time by study 
group. Rates of detection of plasma viral loads of more 
Home-based care 
(n=859)
Facility-based care 
(n=594)
Outpatient presentations (visits/patients) 6691 (8/1) 15 242 (26/1)
New disorder diagnosed* (diagnoses/patients) 3908 (5/1) 5751 (10/1)
Diagnosis by classification†
Infectious and parasitic 2063 (53%) 3086 (54%)
Nervous system 521 (13%) 676 (12%)
Skin and subcutaneous tissue 447 (11%) 597 (10%)
Musculoskeletal system and connective tissue 343 (9%) 548 (10%)
Digestive system 128 (3%) 209 (4%)
Respiratory system 98 (3%) 193 (3%)
Genitourinary system 65 (2%) 73 (1%)
Circulatory system 61 (2%) 117 (2%)
Endocrine, nutritional, and metabolic 60 (2%) 80 (1%)
Mental and behavioural disorders 38 (1%) 56 (1%)
Blood and blood-forming organs and some 
disorders aﬀ ecting immune mechanisms
31 (1%) 30 (<1%)
Neoplasms 25 (1%) 24 (<%)
Pregnancy, childbirth, and puerperium 18 (<1%) 54 (1%)
Other 10 (<1%) 8 (<1%)
Data are n (%) unless otherwise stated. *During outpatient presentation in which a medical oﬃ  cer was seen. 
†Diagnoses classiﬁ ed according to WHO International Classiﬁ cation of Diseases.23 Only primary diagnosis listed. 
Table 4: Frequency of outpatient attendance overall and in which a physician was seen and a new clinical 
disorder diagnosed
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than 500 copies per mL after a 6-month visit were much 
the same in both groups. Also similar were the composite 
rates of either plasma RNA viral loads of more than 
500 copies per mL after a 6-month visit in those who had 
undetectable viral loads at 6 months, or an increase in 
plasma RNA viral load of 1000 copies per mL between 
two consecutive tests in those who had detectable viral 
loads at 6 months. 184 (24%) patients having home and 
145 (27%) facility care either had virological failure, were 
lost to follow-up, or withdrew from the trial (adjusted rate 
ratio [RR] 0·88, 95% CI 0·70–1·10).
Mortality rates were much the same in the two groups 
during the study (ﬁ gure 2). Combined mortality rates 
per 100 person-years were 16·47 (95% CI 13·69–19·82) 
during the ﬁ rst 5 months after treatment started, 6·69 
(4·94–9·05) for 6–11 months, 2·71 (1·92–3·84) for 
12–23 months, and 0·97 (0·54–1·76) for 24 months and 
after. By the end of the study, 566 (66%) participants in 
the home group and 377 (63%) in the facility group were 
alive, receiving follow-up, and had undetectable plasma 
viral loads.
Admission diagnoses were similar in both groups 
(table 3). 20 (13%) patients who were admitted died (15 on 
home and ﬁ ve on facility care) and eight (5%)  worsened 
and requested discharge (six on home and two on facility 
care)—seven died subsequently. Table 4 shows frequency 
of outpatient attendance at clinic, number of presentations 
in which a new diagnosis was made, and new diagnoses 
by number and type. Distribution of diagnoses was 
similar between groups and more than half were 
infectious and parasitic disease. 
CD4-cell counts increased rapidly in both groups 
(ﬁ gure 3). 748 (87%) participants in home care and 
521 (88%) in facility care were tested for CD4-cell count 
at least once after starting treatment, with median 
intervals between baseline and ﬁ nal tests of 32 months 
(IQR 25–39) for home and 29 months (23–35) for facility. 
608 (81%) in home and 419 (80%) in facility had CD4-cell 
counts of greater than 200 cells per μL at the ﬁ nal visit. 
Counts at this visit were lower than baseline in 32 (4%) 
of those in home compared with 29 (6%) in facility care. 
At routine clinical and counselling reviews, home 
participants reported complete adherence to therapy in 
the past 28 days in 3698 of 3951 (94%) visits compared 
with 2527 of 2768 (91%) visits made by facility participants 
(ﬁ gure 4). Patients were too sick to be interviewed in a 
further 78 (2%) home-group and 39 (1%) facility-group 
visits. Only two patients, both in home-based care, 
refused to answer adherence questions—saying they 
were in a hurry to return home.
138 (16%) of patients in home care had a drug 
substitution at a median 9 months (IQR 2–24) versus 
123 (21%) in facility care at 8 months (3–22) after 
treatment started. Most substitutions were because of 
adverse reactions to antiretroviral therapy (table 5). Only 
one person in home-based and two in facility-based care 
had their ﬁ rst-line treatment changed to second-line.
Table 6 shows mean yearly health services cost per 
patient calculated during 4 years, (including capital and 
recurrent expenses, and those of the starting phase and 
subsequent years). A large proportion of the costs were 
for drugs and staﬀ  salaries. The main cause of excess 
expenditure for the facility-based group was the increased 
number of contacts with health staﬀ —especially with 
nurses and medical oﬃ  cers. These costs outweighed 
those of transport for ﬁ eld oﬃ  cers in the home-based 
group. Patient costs (transport of patient and companion, 
lunches, child care, and time lost from work) were much 
higher for the facility-based than for the home-based 
group (table 6). 
During the ﬁ rst year, when many visits were needed 
to start antiretroviral therapy, median yearly costs 
incurred by every patient were higher in facility than in 
home (table 6). Much of this expense was for transport. 
After the ﬁ rst year, patient costs for the home-based 
group were fairly low but remained high for the 
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facility-based group, showing the economic burden of 
monthly clinic visits. Overall, the median cost of a clinic 
visit was $2·30—about 13% of reported monthly cash 
incomes for men and 20% for women. 
Discussion
We have shown that a home-based HIV-care strategy with 
trained lay workers supporting drug delivery and 
monitoring patients was as eﬀ ective as was a nurse-led and 
doctor-led clinic-based strategy for prevention of virological 
failure, mortality, and other adverse outcomes. For our 
primary endpoint of virological failure, the adjusted RR 
was contained between the pre-speciﬁ ed equivalence limits 
of 0·69 to 1·45. Results were similar for other endpoints. 
The home-based strategy did not result in higher costs for 
the health service. Moreover, home-based care was slightly 
cheaper than facility-based care by about $45 per patient 
per year, or 6% of the total cost. Costs incurred by patients 
to access care were much less for those in the home group 
than for those receiving facility-based care.
We have identiﬁ ed a strategy to provide eﬀ ective HIV 
care in the many settings in Africa in which clinical staﬀ  
are scarce and patient access to clinics is diﬃ  cult. Our 
ﬁ ndings were achieved in a standard resource-constrained 
health-service setting. Mortality rates in our facility-based 
group of about six deaths per 100 person-years and 
virological failure rates of nine per 100 person-years were 
better than or at least as good as were those reported from 
most other settings. Other researchers8,10,16,21,24–26 have 
reported mortality rates ranging from six to more than 
15 deaths per 100 person-years and virological failure 
rates20–22,27,28 from 15% to more than 40% for 12–24 months. 
Thus, ﬁ ndings from our home-based care strategy were 
compared with a well functioning facility-based model 
and identiﬁ ed to be equivalent. Mortality rates in developed 
countries are about two deaths per 100 person-years27 and 
most of the increased mortality in Africa takes place 
during the ﬁ rst year of follow-up,29 as we identiﬁ ed. This 
mortality rate could be reduced through starting of 
antiretroviral therapy earlier than it is at present, but how 
people with HIV infection who need treatment can be 
identiﬁ ed early and encouraged to seek care is less clear, 
and needs to be investigated. Our study shows that 
community-based approaches would be important. 
We transferred care from the clinic to trained lay 
workers visiting homes of patients. The costs of the home 
visits were oﬀ set by the savings from reduced attendence 
at clinic—thus, 75% fewer clinic visits were made by 
patients in the home-based group, and 50% fewer 
Stavudine Zidovudine Lamivudine Nevirapine Efavirenz
HBC FBC HBC FBC HBC FBC HBC FBC HBC FBC
Starting ART 476 (55%) 330 (56%) 382 (44%) 263 (44%) 859 (100%) 594 (100%) 655 (76%) 457 (77%) 204 (24%) 137 (23%)
Changed to another ART 70 (15%) 56 (15%) 33 (9%) 22 (9%) 7 (1%) 2 (<1%) 38 (6%) 37 (8%) 18 (9%) 25 (18%)
Main reason for change 
Adverse reaction 65 (93%) 53 (95%) 26 (79%) 20 (91%) 6 (86%) 2 (100%) 16 (42%) 14 (38%) 8 (44%) 10 (40%)
Intolerance* 1 (1%) 0 2 (6%) 2 (9%) 0 0 0 1 1 (6%) 0
ART out of stock 1 (1%) 0 0 0 0 0 0 1 0 0
Patient sick, drug burden reduced 0 0 1 (3%) 0 0 0 0 0 0 0
Pregnancy 0 0 0 0 0 0 0 0 8 (44%) 15 (60%)
Started tuberculosis drug 0 0 0 0 0 0 22 (58%) 21 (57%) 1 (6%) 0
Other reasons 3 (4%) 3 (3%) 4 (12%) 0 1 (14%) 0 0
Time to change (months)† 23 (8–28) 22 (9–26) 2 (2–5) 2 (1–5) 8 (2–12) 3,4 3 (3–11) 4 (3–11) 9 (4–17) 11 (4–22)
Data are n (%) or median (IQR). HBC=home-based care, n=859. FBC=facility-based care, n=594. One home-care and one facility-care patient started treatment with tenofovir and neither had a drug substitution. 
ART=antiretroviral therapy. *Mostly vomiting, nausea, headache, and changes in nail pigmentation. †Actual times for the two patients in facility-based care who started on lamivudine and changed are given.
Table 5: Distribution of drug substitutions to ﬁ rst-line regimens according to initial regimen
Home-based care Facility-based care
Health-service costs
Staﬀ * 359 139 (23·0%) 319 016 (29·1%)
Transport 66 859 (4·3%) 29 204 (2·7%)
Drugs 822 509 (52·8%) 548 339 (50·1%)
Laboratory and clinical 80 850 (5·2%) 53 900 (4·9%)
Sensitisation 31 000 (2.·0%) 20 666 (1·9%)
Training and workshops 33 472 (2·2%) 22 315 (2·0%)
Utilities 17 313 (1·1%) 11 542 (1·1%)
Supervision and overheads 84 452 (5·4%) 55 818 (5·1%)
Capital 61 970 (4·0%) 35 073 (3·2%)
Total 1 557 564 (100%) 1 095 873 (100%)
Cost per patient per year 
(mean)
793 838
Patient costs to access care (per patient) 
Transport, lunch, and 
childcare costs (median)
9 39
Lost work time (yearly) 9 15
Total (ﬁ rst year) 29 60
Total per year (after ﬁ rst year) 18 54
Data are US$ (%) or US$ (SD), unless otherwise indicated. *Includes all staﬀ . 
Calculated from 2005–08 mean exchange rate of 1732 Ugandan shillings to US$1. 
Table 6: Costs of health-service delivery and costs incurred by patients to 
access care (in US$)
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consultations with a doctor took place when a new clinical 
disorder was recorded. We recorded no negative eﬀ ect on 
survival, plasma viral load, or other outcomes. Patients 
had regular counselling and adherence support, especially 
in the home group in which support was personalised 
and often provided by the same individual. This support 
could have had a major positive eﬀ ect on outcomes. Such 
an approach should be achievable throughout Africa 
since counsellors and other support staﬀ  are more easily 
available and rapidly trained than are clinical staﬀ  and 
incur much less expense for health services. A large 
randomised trial30 at two sites in Uganda and one in 
Zimbabwe recorded health-service costs of $846 (2008 
exchange rate) for a model of laboratory and clinical 
monitoring at a health facility, which is similar to $793 in 
our home group and $838 in our facility group. 
Costs of access to care are a major burden for most 
African people, especially for those living in rural areas, 
because cash incomes are very low. In our study, one clinic 
visit was 15–20% of monthly earnings for most people. In 
Africa, high travel costs relative to income are major 
determinants of poor access to care, late presentation, 
poor adherence, and low retention of people in 
antiretroviral-therapy programmes.4,14,31 Our study shows 
that home-based care could substantially reduce costs for 
patients and this outcome might have a major beneﬁ cial 
eﬀ ect on their long-term adherence and retention.
In our study, TASO changed treatment to second-line 
therapy for three people only, which was substantially 
fewer than those who had falls in CD4-cell counts to less 
than their baseline or virological failure, showing the 
major diﬀ erences in the diagnostic accuracy of clinical 
and laboratory assessments. When to change HIV treat-
ment is a dilemma in many settings in Africa because of 
poor availability and high costs of second-line regimens 
and the absence of information about resistance to 
antiretroviral therapy—a situation that is unlikely to 
greatly change in the near future. We should, therefore, 
identify means to achieve the best possible adherence to 
extend the life of existing drugs. Our results suggest that 
community-based support of patients receiving anti-
retroviral therapy could lead to high adherence. 
Very few studies have been done in which models of care 
are randomly assigned because of strong preferences of 
some individuals for a speciﬁ c method of care and the role 
of stigma, which might result from HIV status disclosure—
eg, if a ﬁ eld worker from a known AIDS support 
organisation visits a patient in the community. We 
overcame these diﬃ  culties by developing a partnership 
with the service provider, the community, and with patients 
from the beginning when the research question was 
deﬁ ned, and then held regular meetings with stakeholders 
to discuss diﬃ  culties and provide information. No 
monetary incentives were provided to either the service 
provider or patients. Only 41 (3%) of participants refused 
to join the trial or later withdrew and cited stigma as a 
reason. All received antiretrovirals from TASO or other 
providers. The importance and eﬀ ects of stigma in the 
long term when patients have sustained improved health 
and, for example, resumed normal relationships, is 
unclear. However, we have shown that community-based 
HIV care is feasible and that stigma is probably not an 
impediment to increasing coverage in settings in which 
trust and good relations between service providers and the 
community are present.
Our study could have been aﬀ ected by selection bias, 
but numbers of refusals and withdrawals were low and 
almost identical in both groups. Most people who 
withdrew were alive at the end of the study—survival 
status was unknown for just 51 (4%) of participants. More 
were recruited in the home group than in the facility 
group but many more in the home group were screened, 
suggesting that this imbalance arose by chance. Median 
baseline CD4-cell count was also lower in the home 
group than in the facility group, but again this ﬁ nding 
was probably attributable to chance (and was adjusted for 
in the analysis). These imbalances show the weakness of 
cluster-randomised trials32 in achievement of balance 
through randomisation, even in trials such as ours in 
which a large number of clusters were randomised.  
We have shown that home-based HIV care with 
antiretroviral therapy is an eﬀ ective strategy, which relies 
less on clinical staﬀ  and hospital services than does 
facility-based care and provides large savings for patients. 
Such community-based strategies could enable improved 
and equitable access to HIV treatment—especially in 
areas in which clinical infrastructure is scarce and patient 
access to clinic-based care is poor. 
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